跳至主要内容
临床试验/NCT00926809
NCT00926809Unknown4 期

Helicobacter Pylori Eradication Therapy on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection of Gastric Neoplastic Lesions: a Multicenter, Randomized, Double Blind, and Placebo Controlled Trial

Korean College of Helicobacter and Upper Gastrointestinal Research6 个研究点 分布在 1 个国家目标入组 232 人开始时间: 2008年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
入组人数
232
试验地点
6
主要终点
ulcer healing rate by endoscopic assessment

研究概览

简要总结

This study will evaluate the effect of Helicobacter pylori eradication therapy on the healing of iatrogenic gastric ulcer caused by endoscopic mucosal resection of gastric neoplastic lesions and is a multicenter, randomized, double blind, and placebo controlled trial.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
30 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 30 - 75 years old
  • Early gastric cancer (< 3 cm in size, mucosa confined, differentiated type) or gastric adenoma (< 3 cm in size)
  • Helicobacter pylori positive

排除标准

  • Medication of anti-secretory drugs (proton pump inhibitors, H2-receptor antagonists, antacid, bismuth compound)
  • History of Helicobacter pylori eradication
  • History of gastric surgery or other cancers
  • Major comorbidities
  • Medication of ASA, NSAIDS, steroids, anti-coagulants

研究组 & 干预措施

Eradication

Active Comparator

Helicobacter pylori eradication

干预措施: Lansoprazole (proton pump inhibitor), amoxicillin, clarythromycin (Drug)

No eradication

Placebo Comparator

No eradication for Helicobacter pylori

干预措施: Lansoprazole (proton pump inhibitor), placebo (Drug)

结局指标

主要结局

ulcer healing rate by endoscopic assessment

时间窗: 8 weeks

次要结局

  • ulcer reduction rate by endoscopic assessment(8 weeks)

研究者

发起方
Korean College of Helicobacter and Upper Gastrointestinal Research
申办方类型
Other

研究点 (6)

Loading locations...

相似试验

H. Pylori Eradication on Healing of Iatrogenic... | 临床试验